What to look out for at ESMO 2022

esmo_2019_big

The annual meeting of the European Society of Medical Oncology (ESMO) kicks off in Paris on September 9, and early indications are the event could be full of practice-changing data.

In the runup to the event, The Pharma Letter spoke with medical oncologist and ESMO Council member Antonio Passaro for an inside look at some of the leading themes and key presentations at the event.

As a member of both the ESMO Lung Cancer Faculty and the board responsible for drawing up lung cancer guidelines in his native Italy, Dr Passaro is naturally keen to draw attention to what he regard as “one of the most important presentations, that will be discussed for months to come, about the correlation between high levels of pollution and lung cancer.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology